The honest answer is that it depends entirely on individual circumstances
A3192), the Danish Medical Associations Research Foundation (grant no
Confirm your eligibility criteria: Understand the BMI and condition thresholds that determine GLP-1 eligibility so you're not surprised by the intake outcome
Lillys triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea
Across the whole program, oral semaglutide was shown to be effective in helping patients achieve glycemic control and reducing body weight
[11] [13] Suppression of glucagon : They reduce the secretion of glucagon, a hormone that raises blood glucose, thereby further improving glycaemic control